Litcius/Paper detail

SARS-CoV-2 M <sup>pro</sup> inhibitors: identification of anti-SARS-CoV-2 M <sup>pro</sup> compounds from FDA approved drugs

Shiv Bharadwaj, Esam I. Azhar, Mohammad Amjad Kamal, Leena H. Bajrai, Amit Dubey, Kanupriya Jha, Umesh Yadava, Sang Gu Kang, Vivek Dhar Dwivedi

2020Journal of Biomolecular Structure and Dynamics47 citationsDOIOpen Access PDF

Abstract

studies against SARS-CoV-2 infection.Communicated by Ramaswamy H. Sarma.

Topics & Concepts

Docking (animal)ChemistryCoronavirusIn vivoStereochemistrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DarunavirPharmacologyVirologyCoronavirus disease 2019 (COVID-19)MedicineVirusBiologyViral loadPathologyDiseaseBiotechnologyInfectious disease (medical specialty)NursingAntiretroviral therapyComputational Drug Discovery MethodsSARS-CoV-2 and COVID-19 Researchthermodynamics and calorimetric analyses
SARS-CoV-2 M <sup>pro</sup> inhibitors: identification of anti-SARS-CoV-2 M <sup>pro</sup> compounds from FDA approved drugs | Litcius